DENURIL 60MG/ML INJECTION

DENURIL 60MG/ML INJECTION is not recommended in patients with a history of certain cancers, such as multiple myeloma or bone metastases. It is important to discuss your medical history and any previous or current cancer diagnoses with your healthcare provider before starting this medication.

DENURIL 60MG/ML INJECTION can cause side effects like injection site reactions, back and musculoskeletal pain, infections, abdominal pain, headache, and low blood phosphate levels. Rare but serious side effects may include osteonecrosis of the jaw, atypical femoral fractures, hypocalcemia, and severe skin reactions.

DENURIL 60MG/ML INJECTION use has been associated with a slightly increased risk of jaw osteonecrosis (ONJ). Suppose you have dental implants or are considering getting them. In that case, it is important to discuss this with your dentist and healthcare provider to assess DENURIL 60MG/ML INJECTION's potential risks and benefits.

DENURIL 60MG/ML INJECTION is not approved for use in children and adolescents with osteoporosis. The safety and efficacy of this medication have not been established in this population.

Yes, DENURIL 60MG/ML INJECTION is approved for the treatment of osteoporosis in men at increased risk of fractures. It can help improve bone density and reduce fracture risk in male patients with osteoporosis.

DENURIL 60MG/ML INJECTION is primarily eliminated through the kidneys, so caution is advised in patients with severe renal impairment or end-stage renal disease. Your healthcare provider will assess the potential risks and benefits based on your renal function.

It is important to inform your doctor or pharmacist about all the medications you are currently taking, including prescription and over-the-counter drugs, vitamins, and herbal supplements, as DENURIL 60MG/ML INJECTION may interact with them.

Attend all scheduled appointments to monitor treatment. Inform your doctor about your medical history, including infections, liver or kidney disease, and allergies. Seek immediate medical attention for severe reactions. Calcium levels may be affected, so monitor levels and ensure adequate calcium and vitamin D intake. Pregnant/breastfeeding women should consult a doctor. Avoid vaccines during treatment. Maintain good oral hygiene and have regular dental exams due to the risk of jaw osteonecrosis.

The active ingredient in DENURIL 60MG/ML INJECTION is DENOSUMAB.

DENURIL 60MG/ML INJECTION is primarily used to treat osteoporosis and prevent bone fractures. While bone health is related to conditions like arthritis, its primary approved uses are for bone density issues and certain cancers causing bone loss, not specifically for arthritis inflammation itself. Your doctor will determine if it's appropriate for your condition.

DENURIL 60MG/ML INJECTION contains Denosumab, which is a monoclonal antibody. It works by targeting a protein called RANKL, which is involved in bone breakdown. By blocking RANKL, Denosumab reduces the activity of cells that break down bone, thus increasing bone density and reducing the risk of fractures in osteoporosis.